Cardiol Therapeutics announces Phase II ARCHER results in myocarditis

Cardiol Therapeutics (CRDL) announced topline results from ARCHER, the company’s Phase II clinical trial in patients with acute myocarditis. In the two primary endpoints – extracellular volume and global longitudinal strain – CardiolRx showed an improvement in ECV compared to placebo following 12 weeks of double-blind therapy, with no significant difference observed in GLS in a population that had preserved left ventricular function at baseline, the company said in a statement. The reduction in ECV was associated with improvements over placebo in multiple pre-specified cardiac magnetic resonance imaging endpoints, including a significant reduction in LV mass, it added. Cardiol said, “The ARCHER trial results provide compelling clinical proof of concept for CardiolRx and strongly support advancing the clinical development of CardiolRx and CRD-38 in cardiomyopathies, heart failure, and myocarditis. Consistent with findings from Cardiol’s Phase II MAvERIC trial in recurrent pericarditis, CardiolRx was shown to be safe and well tolerated. The ARCHER results have been submitted for presentation at an upcoming scientific meeting and will be submitted for publication.”